Cargando…
Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469818/ https://www.ncbi.nlm.nih.gov/pubmed/32914067 http://dx.doi.org/10.1002/iju5.12181 |
| _version_ | 1783578471930265600 |
|---|---|
| author | Takeuchi, Ario Shiota, Masaki |
| author_facet | Takeuchi, Ario Shiota, Masaki |
| author_sort | Takeuchi, Ario |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7469818 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74698182020-09-09 Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma Takeuchi, Ario Shiota, Masaki IJU Case Rep Editorial Comment John Wiley and Sons Inc. 2020-06-25 /pmc/articles/PMC7469818/ /pubmed/32914067 http://dx.doi.org/10.1002/iju5.12181 Text en © 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Editorial Comment Takeuchi, Ario Shiota, Masaki Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title | Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title_full | Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title_fullStr | Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title_full_unstemmed | Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title_short | Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| title_sort | editorial comment to resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma |
| topic | Editorial Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469818/ https://www.ncbi.nlm.nih.gov/pubmed/32914067 http://dx.doi.org/10.1002/iju5.12181 |
| work_keys_str_mv | AT takeuchiario editorialcommenttoresumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma AT shiotamasaki editorialcommenttoresumptionofantiprogrammedcelldeath1monotherapyforsevereimmunerelatedadverseeventsexperiencedpatientwithrenalcellcarcinoma |